Table 2. Cost components and unit costs considered in the analytical model for the Brazilian Amazon (2020 US$).
| Items | Base-case | Variation | Distribution | Source |
|---|---|---|---|---|
| P. vivax diagnosis | ||||
| Thick blood smear | 0.808 | 0.166–1.238e | Triangular (min: 0.166; max: 1.238) | [19,20] |
| Microscope | 0.461 | 0.370–0.553e | Triangular (min: 0.370; max: 0.553) | [19,20] |
| Microscope maintenance | 0.034 | 0.029–0.043e | Triangular (min: 0.029; max: 0.043) | [19,20] |
| Health workers | 2.154 | 1.722–2.584e | Triangular (min: 1.722; max: 2.584) | [19,20] |
| Yearly training (microscopist) | 3.506 | 2.805–4.208e | Triangular (min: 2.805; max: 4.208) | [19,20] |
| Treatment scheme | ||||
| CQ 3 days + PQ 7 daysa | 0.173 | 0.138–0.208f | Triangular (min: 0.138; max: 0.208) | [21] |
| CQ 3 days + weekly supervised PQb | 0.256 | 0.205–0.307 f | Triangular (min: 0.205; max: 0.307) | [21] |
| CQ 3 days + weekly CQc | 0.403 | 0.322–0.484f | Triangular (min: 0.322; max: 0.484) | [21] |
| G6PDd diagnosis d | ||||
| - Training | 0.358 | 0.286–0.430f | Triangular (min: 0.286; max: 0.430) | [14] |
| - Health worker | 1.077 | 0.862–1.292e | Triangular (min: 0.862; max: 1.292) | [19,20] |
| - Test kit cost (SD Biosensor Standard G6PD test)–single test | 8.728 | 6.982–10.474f | Triangular (min: 6.982; max: 10.474) | [14] |
| - Supplies (SD Biosensor Standard G6PD test)—single test | 0.224 | 0.184–0.330g | Triangular (min: 0.184; max: 0.330) | [14,22] |
| Analyzer (SD Biosensor Standard G6PD test)–single test | 2.436 | 1.593–4.733g | Triangular (min: 1.593; max: 4.733) | [14] |
| Medical assistance to the G6PDd patient treated with PQ | ||||
| Pre-admission tests | 6.615 | 5.973–7.044e | Triangular (min: 5.973; max: 7.044) | [19,20] |
| Medical appointments | 2.865 | - | [23] | |
| Hospitalization (AIH) | 123.022 | 98.417–147.626e | Gamma (α: 1.2963; ʎ: 0.0105) | [19,20] |
a: treatment indicated for patients with G6PD enzyme activity greater than or equal to 30% of normal
b: treatment (0.75mg/kg/week PQ per 8 weeks, supervised) indicated for patients with G6PD enzyme activity less than 30% of normal
c: treatment indicated for pregnant patients
d: G6PDd diagnosis costs detailed in S1 Box
e: variation identified in economic studies previously published by our research group
f: variation of +/-20% from base-case
g: variation calculated considering the data from the municipalities separately (number of cases, number of health units and equipment used), represents the variation between the two municipalities evaluated.